Synergy Pharmaceuticals (SGYP) Upgraded by BidaskClub to “Sell”

BidaskClub upgraded shares of Synergy Pharmaceuticals (NASDAQ:SGYP) from a strong sell rating to a sell rating in a research report sent to investors on Wednesday morning.

SGYP has been the topic of a number of other research reports. HC Wainwright set a $8.00 target price on Synergy Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, October 18th. BTIG Research reaffirmed a buy rating and set a $7.00 target price on shares of Synergy Pharmaceuticals in a research note on Tuesday, November 14th. Cantor Fitzgerald reaffirmed a buy rating on shares of Synergy Pharmaceuticals in a research note on Thursday, February 1st. Zacks Investment Research raised Synergy Pharmaceuticals from a hold rating to a buy rating and set a $2.25 target price on the stock in a research note on Tuesday, February 6th. Finally, CIBC reaffirmed a market perform rating on shares of Synergy Pharmaceuticals in a research note on Friday, January 5th. Two analysts have rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $8.28.

Synergy Pharmaceuticals (NASDAQ:SGYP) opened at $2.03 on Wednesday. The company has a market capitalization of $481.74, a P/E ratio of -1.75 and a beta of 1.13. Synergy Pharmaceuticals has a 52 week low of $1.68 and a 52 week high of $6.45. The company has a debt-to-equity ratio of -68.13, a quick ratio of 3.88 and a current ratio of 4.26.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. MetLife Investment Advisors LLC purchased a new stake in shares of Synergy Pharmaceuticals in the fourth quarter valued at approximately $124,000. HBK Sorce Advisory LLC purchased a new stake in shares of Synergy Pharmaceuticals in the fourth quarter valued at approximately $103,000. California State Teachers Retirement System boosted its holdings in shares of Synergy Pharmaceuticals by 7.4% in the fourth quarter. California State Teachers Retirement System now owns 392,004 shares of the biopharmaceutical company’s stock valued at $874,000 after purchasing an additional 26,859 shares during the period. Virtu Financial LLC boosted its holdings in shares of Synergy Pharmaceuticals by 500.3% in the fourth quarter. Virtu Financial LLC now owns 173,704 shares of the biopharmaceutical company’s stock valued at $387,000 after purchasing an additional 144,768 shares during the period. Finally, BlackRock Inc. boosted its holdings in shares of Synergy Pharmaceuticals by 8.7% in the fourth quarter. BlackRock Inc. now owns 21,998,125 shares of the biopharmaceutical company’s stock valued at $49,056,000 after purchasing an additional 1,761,725 shares during the period. Hedge funds and other institutional investors own 60.68% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://ledgergazette.com/2018/02/18/synergy-pharmaceuticals-sgyp-upgraded-by-bidaskclub-to-sell.html.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Analyst Recommendations for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply